Global X Genomics & Biotechnology ETF GNOM

Morningstar Medalist Rating

Morningstar’s Analysis GNOM

Will GNOM outperform in the future?

Get our overall rating based on a fundamental assessment of the pillars below.

null Morningstar Automated Analysis

Morningstar Automated Analysis

Summary

Global X Genomics & Biotechnology ETF holds a quantitatively derived Negative Morningstar Medalist Rating. The rating indicates the model sees limited potential for the strategy to outperform peers on a risk-adjusted basis over a full market cycle.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings GNOM

  • Current Portfolio Date
  • Equity Holdings—
  • Bond Holdings—
  • Other Holdings—
  • % Assets in Top 10 Holdings53.2
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

Praxis Precision Medicines Inc Ordinary Shares

5.125M
Healthcare

BioMarin Pharmaceutical Inc

4.885M
Healthcare

Vertex Pharmaceuticals Inc

4.785M
Healthcare

Moderna Inc

4.735M
Healthcare

Bio-Techne Corp

4.725M
Healthcare

Qiagen NV

4.665M
Healthcare

BioNTech SE ADR

4.565M
Healthcare

Guardant Health Inc

3.724M
Healthcare

Arrowhead Pharmaceuticals Inc

3.463M
Healthcare

CRISPR Therapeutics AG

3.283M
Healthcare

Sponsor Center